The Ozempic maker and its peers are setting their sights on oral obesity medications to diversify their portfolios and remain ...

We recently published a list of 13 Stocks on Jim Cramer’s Radar Recently. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks on Jim ...

European Commission President Ursula von der Leyen has lost a lawsuit attempting to force her to disclose text messages with ...

From my colleague Jason Mast: The first ever patient has been treated with prime editing, a powerful technology for making ...

Novo Nordisk A/S is partnering with US biotech Septerna Inc. on the development of oral pills for obesity in a deal ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

Shares of Septerna Inc. were soaring in early Wednesday trading after the biotech clinched a partnership with Wegovy and Ozempic parent Novo Nordisk to collaborate on oral obesity and Type 2 diabetes ...

President Donald Trump’s latest bid to slash prescription drug prices has once again stirred heated debate about the high ...

It seems Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity and cardiometabolic ...

Under the terms of the agreement, Septerna is eligible to receive around $2.2 billion from Novo Nordisk, including more than $200 million in upfront and near-term milestone payments.

Found, the leading specialized weight care telehealth platform developed by obesity specialists, today announced it will offer Wegovy® at $499 per month and Zepbound™ vials ranging from $349 to $699.

GSK is acquiring an experimental medicine from a Cambridge biotech to shore up its drug pipeline and muscle into the ...